Cardiometabolism Disease Area
The Cardiometabolism disease area encompasses a broad range of disorders that affect the cardiovascular system and metabolic processes. This research field is dedicated to understanding the intricate relationships between heart health, blood vessels, and metabolic functions, including how these systems influence each other. Cardiometabolic diseases often involve complex interactions between genetics, lifestyle factors, and environmental influences. By studying these interactions, researchers aim to develop effective prevention strategies, treatments, and therapies. Advanced animal models, clinical studies, and cutting-edge technologies are utilized to investigate the underlying mechanisms and potential interventions. This comprehensive approach is crucial for improving diagnostic methods and therapeutic outcomes in cardiometabolic health.
Metabolic syndrome (MetS) is a bunch of metabolic symptoms comprising hypertension, insulin resistance, obesity, hyperlipidemia and ect. Sedent lifestyle and energy overtaking of modern life is two of the key risk factors of the disease. MetS is a prominent cause of morbidity and mortality internationally and has been become very important area novel therapies investigation in this context to decrease the heavy burden of the disease.
Why Use NHP for Cardiometabolism Disease Research Modeling
Non-human primate (NHP) models are invaluable for cardiometabolism disease research due to their genetic, physiological, and anatomical similarities to humans. These models provide critical insights into gene expression, disease mechanisms, and the effects of treatments. NHPs also accurately simulate chronic disease progression, offering a realistic platform for long-term studies. Their use enhances the translational potential of research, ensuring that new therapies are safe and effective for human applications.
Genetic Similarity
NHPs have genetic compositions closely resembling humans, making them invaluable for cardiometabolism disease research. Their genetic makeup allows researchers to study the expression and regulation of genes involved in cardiovascular and metabolic conditions, providing insights that are highly translatable to human health.
Physiological Resemblance
The physiological systems of NHPs, including their cardiovascular and metabolic functions, are remarkably similar to those of humans. This similarity enables scientists to observe the effects of diseases and treatments on the heart, blood vessels, and metabolism in a way that closely mirrors human responses.
Anatomical Comparability
NHPs share significant anatomical features with humans, particularly in cardiovascular and metabolic systems. This comparability allows for more accurate modeling of disease processes, such as atherosclerosis or insulin resistance, providing a more realistic platform for testing medical interventions.
Chronic Disease Progression
NHPs are ideal for studying the long-term progression of chronic diseases. Their lifespan and disease development patterns are comparable to humans, allowing researchers to monitor the natural history of conditions like diabetes and cardiovascular diseases over extended periods.
Translational Research Potential
The use of NHP models accelerates the translation of basic research findings into clinical applications. By providing a relevant and realistic context for testing new therapies, NHPs help ensure that treatments are both safe and effective before they are applied in human clinical trials.
Superior Platform for Cardiometabolism Research at Prisys
Prisys provides a specialized research platform for cardiometabolic disease, equipped with advanced imaging and diagnostic tools like MRI, DSA, DEXA, and ultrasound. Our team performs complex procedures such as liver and kidney biopsies and DSA-guided drug administration, essential for in-depth research.
Advanced Cardiometabolism Assays
Our facility offers specialized assays, including lipid profiling and glucose metabolism studies, to provide deep insights into cardiometabolic diseases and assess treatment efficacy and safety.
Clinical Transformation
We provide comprehensive clinical research services, from early to late-stage trials, using advanced biomarker analysis and personalized medicine to streamline the translation of treatments.
Drug Modality Support
Prisys supports the evaluation of various drug types, including small molecules, biologics, and gene therapies, focusing on efficacy, safety, and pharmacokinetics in cardiometabolic diseases.
Cardiometabolism Disease Models
|
Cardiovascular Diseases: Coronary artery disease (CAD) Hypertension (high blood pressure) Heart failure Arrhythmias (e.g., atrial fibrillation) Peripheral artery disease (PAD) |
Metabolic Disorders: Metabolic syndrome Dyslipidemia (abnormal cholesterol levels) |
Obesity-related Conditions: Obesity Insulin resistance Hyperinsulinemia |
|
Inflammatory and Thrombotic Conditions: Atherosclerosis Thrombosis Chronic inflammation related to metabolic disorders |
Genetic and Congenital Disorders: Familial hypercholesterolemia Congenital heart defects |
Kidney-related Cardiometabolic Disorders: Chronic kidney disease (CKD) with cardiovascular implications Diabetic nephropathy |
FAQ
What types of cardiometabolic diseases can Prisys model?
Prisys offers models for various cardiometabolic diseases, including cardiovascular diseases (e.g., coronary artery disease, hypertension), metabolic disorders (e.g., Type 2 diabetes, metabolic syndrome), obesity-related conditions, and inflammatory and thrombotic conditions.
Why are NHP models valuable for cardiometabolism research?
NHP models are valuable due to their genetic, physiological, and anatomical similarities to humans, allowing for accurate simulation of chronic disease progression and enhancing the translational potential of research findings.
What specialized assays does Prisys provide for cardiometabolic research?
Prisys offers advanced assays, including lipid profiling, glucose metabolism studies, and other specialized tests, to provide deep insights into disease mechanisms and assess the efficacy and safety of treatments.
How does Prisys support drug modality evaluation?
Prisys supports the evaluation of small molecules, biologics, and gene therapies, focusing on assessing efficacy, safety, and pharmacokinetics, tailored to the unique challenges of cardiovascular and metabolic diseases.
What clinical transformation services does Prisys offer?
Prisys provides comprehensive clinical research services, from early to late-stage trials, using advanced biomarker analysis and personalized medicine approaches to accelerate the translation of treatments into clinical practice.